Results of the SELECT clinical trial, presented at the American Heart Associations 2023 Scientific Sessions (1113 November, Philadelphia, USA), have shown that overweight or obese people without diabetes taking the drug semaglutide for more than three years had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease and lost an average of 9.4% of their body weight
Sleep quality, which often improves with effective protocols
Gary Shaw, DrPH, professor of pediatrics
However, it may fall short for people with significant or hormonal hair loss and lacks robust clinical backing compared to some competitors, and raises concerns for people sensitive to bergamot oil
Treatment with 5FU resulted in the reorganization of mitochondrial networks into filamentous structures (Fig